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Summary
The	newly	developed	AspID	PCR	assay	for	detection	of	Aspergillus	spp.	was	evalu-
ated	with	an	interlaboratory	quality	control	programme	panel	and	human	bronchoal-
veolar	lavage	fluid	(BALF)	samples.	With	the	quality	control	programme,	8	out	of	9	
panel	members	were	correctly	identified.	With	the	clinical	study,	36	BALF	samples	
that	had	been	obtained	from	18	patients	with	invasive	pulmonary	aspergillosis	(IPA)	
and	18	without	IPA	were	investigated.	Sensitivity,	specificity,	positive	and	negative	
likelihood	ratio	for	the	AspID	assay	were	94.1%	(95%	CI	73.3-	99.9),	76.5%	(95%	CI	
50.1-	93.2),	4	(95%	CI	1.7-	9.5)	and	0.1	(95%	CI	0.01-	0.5)	respectively.
K E Y W O R D S
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1  | INTRODUC TION
Invasive	 pulmonary	 aspergillosis	 (IPA)	 remains	 a	 major	 cause	 of	
morbidity	 and	mortality	 among	 severely	 ill	 patients.	 The	 critical	
step	 for	 successful	management	 of	 IPA	 is	 rapid	 initiation	 of	 an-
tifungal	 therapy	 requiring	 early	 and	 reliable	diagnosis.1,2 Several 
diagnostic	 approaches	 including	 antigen	 testing,	 new	 imaging	
methods	 and	 molecular	 approaches	 have	 been	 investigated	 to	
overcome	 current	 limitations,	 such	 as	 limited	 performance	 of	
available	diagnostic	methods,	 long	turnaround	times,	and/or	 lim-
ited	standardisation.3-5	Over	recent	years,	Aspergillus	polymerase	
chain	reaction	(PCR)	has	been	shown	to	be	a	very	promising	tool	
for	 detection	 of	 fungal	 infections	when	 testing	 bronchoalveolar	
lavage	 fluid	 (BALF)	 from	 immunocompromised	 patients.6-11	 The	
newly	developed	AspID	(OLM	Diagnostics,	Newcastle,	UK)	assay	
is	a	multiplex	real-	time	PCR	assay	designed	to	detect	clinically	rel-
evant	Aspergillus	 spp.	 This	 assay	 targets	 a	 pan	Aspergillus	 target	
and	simultaneously	an	Aspergillus terreus	target	for	differentiation	
of	Aspergillus terreus	vs	non-	terreus	Aspergillus	spp.	This	is	of	par-
ticular	interest	as	changing	epidemiology	with	an	increase	in	non-	
fumigatus	Aspergillus	 infections	has	been	observed	over	the	past	
decades.12
In	 this	 study,	 the	 performance	 of	 the	 new	 AspID	 PCR	 assay	
was	 investigated	 for	 the	 first	 time	using	both	 the	Quality	Control	
for	Molecular	Diagnostics	(QCMD)	2016	Aspergillus	spp.	DNA	EQA	
Programme	panel	and	human	BALF	samples.
2  | MATERIAL AND METHODS
The	 accuracy	 of	 the	AspID	was	 determined	 utilising	 the	QCMD	
2016 Aspergillus	 spp.	 DNA	 EQA	 Programme	 panel.	 The	 panel	
consisted	 of	 9	 members	 including	 Aspergillus fumigatus	 DNA	
(n	=	3),	Aspergillus fumigatus	conidia	 (n	=	3),	and	negatives	 (n	=	3).	
Members	 were	 either	 spiked	 in	 TE	 puffer,	 synthetic	 sputum,	 or	
in	plasma	matrix.	In	addition,	36	BALF	samples	obtained	from	18	
patients	with	IPA	and	18	patients	without	IPA	were	investigated.	
Samples	were	obtained	between	2013	 and	2016	 at	 the	Medical	
University	of	Graz,	Austria.	BALF	samples	were	 stored	at	−70°C	
immediately	after	collection	and	have—in	part—been	used	in	stud-
ies	 published	 recently.4,6,13-15	 Patients	 were	 classified	 as	 having	
IPA	if	BALF	galactomannan	(GM)	levels	showed	an	optical	density	
index	 of	 >3.0	 and	 patients	 had	 clinical	 and	 radiological	 findings	
compatible	with	 presence	 of	 IPA,	 as	 suggested	 by	D’Haese	 and	
colleagues.16	 Patients	 without	 IPA	 had	 BALF-	GM	 levels	 of	 <0.5	
and	no	clinical	or	radiological	findings	suggestive	for	presence	of	
IPA.	Patients	were	matched	1:1	according	 to	 IPA	status,	primary	
underlying	 disease,	 and	 intensive	 care	 unit	 admission.	 For	 this	
study,	diagnosis	of	IPA	was	based	on	high	BALF-	GM	levels,	clinical	
and	 radiological	 findings.	We	did	not	utilise	 the	 revised	EORTC/
MSG	criteria,	as	these	criteria	are	designed	for	diagnosis	of	inva-
sive	 fungal	 infections	 in	patients	with	active	malignancies	or	 se-
verely	immunocompromised	patients	only,17	and	are	therefore	not	
applicable	to	a	significant	proportion	of	our	study	population	with	
mixed	underlying	diseases.
BALF	 samples	 were	 thawed	 and	 immediately	 tested	 for	 pres-
ence	of	Aspergillus	DNA	 in	an	 International	Standard	Organization	
(ISO	 9001:2008)-	certified	 laboratory,	 the	 Molecular	 Diagnostics	
Laboratory,	 IHME,	 Medical	 University	 of	 Graz.	 Investigators	 per-
forming	 PCR	were	 blinded	 to	 IPA	 status.	 BALF	 and	QCMD	 panel	
samples	were	processed	in	the	same	way.	Aspergillus	DNA	was	ex-
tracted	on	the	NucliSens®	easyMAG™	platform	(bioMérieux,	Marcy-	
l′Etoile,	France)	with	the	NucliSens®	easyMAG™	accessory	products	
(bioMerieux)	 using	 the	 specific	 B	 protocol.	 The	 input	 volume	was	
400	μL.	 After	 the	 lysis	 step	 (10	min	 in	 NucliSens®	 lysis	 buffer	 at	
room	temperature),	4	μL	of	internal	extraction	control	(IEC)	included	
in	the	AspID	assay	was	added.	The	extracted	DNA	was	eluted	auto-
matically	with	40	μL	of	elution	buffer.	For	qPCR	and	detection	with	
the	AspID,	7	μL	of	the	master	mixture	and	3	μL	of	the	extracted	sam-
ple	were	pipetted	into	a	well	of	a	PCR	plate	followed	by	amplifica-
tion	and	detection	on	the	LC	480	II	instrument	(Roche	Diagnostics,	
Penzberg,	Germany).	According	to	the	manufacturer,	AspID	is	sen-
sitive	 to	 10	 copies	 of	 Aspergillus	 target	 template	 and	 may	 give	 a	
positive	result	 if	the	infecting	agent	is	Penicillium	species	(personal	
communication	with	the	manufacturer).
Statistical	analysis	was	performed	using	SPSS,	version	24	(SPSS,	
Inc.,	 Chicago,	 IL,	 USA).	 Receiver	 operating	 characteristic	 (ROC)	
curves	analyses	were	performed	utilising	number	of	AspID	cycles	in	
case	of	 positivity	 and	 area	under	 the	 curve	 (AUC)	 values	 are	pre-
sented	 including	 95%	 CI.	 Optimal	 cut-	offs	 were	 calculated	 using	
Youdens	 index.	 A	 two-	sided	P-	value	 <.05	was	 considered	 statisti-
cally	significant.
3  | RESULTS
When	the	accuracy	of	the	AspID	was	determined	with	the	QCMD	
panel,	 5	 out	 of	 6	 Aspergillus	 positive	 samples	 tested	 positive	 for	
Aspergillus	and	negative	for	Aspergillus terreus.	The	remaining	sample	
turned	out	to	be	false	negative.	The	false	negative	sample	contained	
Aspergillus fumigatus	DNA	in	a	TE	buffer	solution	and	was	classified	
as	“educational”	sample	(ie	containing	low	amount	of	fungal	DNA).	
All	Aspergillus	negative	samples	were	correctly	identified	as	negative	
with	the	AspID	PCR	assay.
QCMD	panel	characteristics	and	results	are	displayed	in	Table	1,	
characteristics	 of	 patients	 with	 and	 without	 IPA	 are	 displayed	 in	
Table	2.	When	36	BALF	samples	were	investigated	with	the	AspID 
assay,	 2	 samples,	 including	 one	 from	 a	 patient	 with	 IPA	 and	 one	
from	 a	 patient	without	 IPA,	 showed	 inhibition	 and	were	 excluded	
from	analysis.	Twenty	BALF	samples	were	found	to	be	positive	for	
Aspergillus	 and	negative	 for	Aspergillus terreus	 and	14	negative	 for	
both	targets.	When	AspID	results	were	compared	to	those	obtained	
from	BALF	GM	determination,	29	(85.3%)	were	found	to	be	concor-
dant	 and	5	 (14.7%)	discordant.	Overall,	 16/17	BALF	 samples	 from	
patients	with	IPA	turned	out	as	true	positive	and	one	as	false	neg-
ative.	Thirteen	out	of	17	BALF	samples	 from	patients	without	 IPA	
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turned	out	as	true	negative	and	4	as	false	positive.	Sensitivity,	spec-
ificity,	positive	(LR+)	and	negative	likelihood	ratio	(LR-	)	for	the	AspID 
assay	including	95%	confidence	interval	(95%	CI)	were	94.1%	(95%	
CI	73.3-	99.9),	76.5%	(95%	CI	50.1-	93.2),	4	(95%	CI	1.7-	9.5)	and	0.08	
(95%	CI	0.01-	0.5)	respectively.	Positive	AspID	results	from	patients	
with	 IPA	 (true	positive)	 showed	a	median	crossing	point	 (cp)	value	
of	25.5,	whereas	positive	AspID	 results	 from	patients	without	 IPA	
(false	positives)	showed	a	median	cp	value	of	36.2	 (P = .011 calcu-
lated	by	Mann-	Whitney-	Test).	Utilising	number	of	cycles	to	positiv-
ity,	ROC	curve	analysis	showed	an	AUC	0.943	(95%	CI	0.860-	1.000)	
for	differentiating	IPA	vs	no	IPA	(Figure	1).	With	Youdens	index,	we	
determined	an	cp	value	optimal	cut-	off	of	≤35.65	for	differentiating	
between	IPA	and	no	IPA	[88.2%	sensitivity	(95%	CI	0.66-	0.97),	94.1%	
specificity	(95%	CI	0.73-	0.99),	LR+	15.0	(95%	CI	2.2-	101.2)	and	LR-	
0.13	(95%	CI	0.03-	0.46)],	while	a	slightly	higher	cp	value	cut-	off	of	
≤37.23	was	associated	with	94.1%	sensitivity	(highest	sensitivity	in	
this	study)	and	83.4%	specificity.	The	latter	cut-	off	resulted	in	a	LR+	
of	5.3	(95%	CI	1.9-	15.0)	and	a	LR-	of	0.07	(95%	CI	0.01-	0.48).	Using	a	
cp	value	cut-	off	of	≤31.25	for	positivity,	a	specificity	of	100%	could	
be	reached	with	an	according	70.6%	sensitivity.	Corresponding	LR+	
was	∞	and	LR−	was	0.29	(95%	CI	0.14-	0.61).
4  | DISCUSSION
In	this	pilot	study,	the	newly	developed	AspID	PCR	assay	was	evalu-
ated	with	 the	 2016	Aspergillus	QCMD	proficiency	 panel	 and	with	
BALF	samples	from	patients	at	risk	for	IPA	for	the	first	time.
With	both	the	QCMD	programme	panel	and	the	BALF	samples	
the	AspID	 PCR	 showed	 an	 excellent	 sensitivity.	 In	 this	 study,	 the	
clinical	sensitivity	of	AspID	was	94%,	which	is	higher	to	that	of	PCR	
assays	for	IPA	diagnosis	reported	in	other	studies.8,9,18	This	may	be	
due	to	the	classification	approach	used	in	this	study	as	a	BALF-	GM	
>3	ODI	was	required	for	IPA	diagnosis.	A	higher	BALF-	GM	level	may	
QCMD sample 
content Matrix
QCMD sample 
status
AspID 
result (cp)
Sample	1 Aspergillus 
negative
TE	buffer Core Negative
Sample	2 Aspergillus 
fumigatus	DNA
TE	buffer Core Positive	
(31.86)
Sample	3 Aspergillus 
fumigatus	DNA
TE	buffer Core Positive	
(30.82)
Sample	4 Aspergillus 
fumigatus	DNA
TE	buffer Educational Negative
Sample	5 Aspergillus 
fumigatus 
conidia
Synthetic	sputum Core Positive	
(33.75)
Sample	6 Aspergillus 
negative
Synthetic	sputum Core Negative
Sample	7 Aspergillus 
fumigatus 
conidia
Synthetic	sputum Educational Positive	
(35.94)
Sample	8 Aspergillus 
negative
Plasma Core Negative
Sample	9 Aspergillus 
fumigatus 
conidia
Plasma Core Positive	
(28.75)
cp,	crossing	point.
TABLE  1 QCMD	panel	characteristics	
and	results	obtained.	The	QCMD	sample	
status	is	designated	as	“Core”	or	
“Educational.”	Participating	laboratories	
are	expected	to	report	core	proficiency	
samples	correctly	within	the	EQA	
challenge/distribution
F IGURE  1 ROC	curve	analysis	for	AspID	for	differentiating	IPA	
vs	no	IPA
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be	associated	with	a	higher	fungal	load	and	may	thus	lead	to	an	over-
estimation	of	the	clinical	AspID	sensitivity	in	this	study.	On	the	other	
hand,	proven	IPA	resulted	in	100%	sensitivity	in	a	previous	study.19 
The	high	clinical	sensitivity	observed	in	this	study	may	only	be	the	
manifestation	of	true	infection	in	those	patients	classified	as	having	
IPA.	For	 routine	clinical	use,	sensitivity	has	 to	be	 investigated	 in	a	
larger	cohort	of	patients	presenting	intermediate	BALF-	GM	levels.
Clinical	specificity	was	slightly	above	76%	with	4	out	of	17	pa-
tients	 without	 IPA	 having	 a	 positive	AspID	 result.	 However,	 false	
positive	samples	showed	significantly	higher	cp	values	indicating	low	
fungal	 DNA	 concentrations.	 False	 positive	 results	may	 have	 been	
observed	due	to	contamination	during	bronchoscopy	and	bronchial	
lavage,	during	the	laboratory	workflow,	or	may	be	a	manifestation	of	
Aspergillus	colonisation	of	the	respiratory	tract	of	the	patient.	All	of	
these	factors	are	associated	with	a	potentially	lower	fungal	burden	
compared	to	true	uncontrolled	infection	and	may	resulting	in	higher	
cp	values.	In	contrast,	all	samples	that	showed	cp	values	of	≤31.25	
were	 associated	with	 IPA.	 Introduction	of	 a	 quantitative	 assay	 in-
cluding	a	quantitation	standard	would	facilitate	the	introduction	of	
a	cut-	off	value	for	discrimination	of	clinically	true	positives	vs	neg-
atives.	This	would	be	of	interest,	as	severely	immunocompromised	
patients	 usually	 receive	mold	 active	 antifungal	 prophylaxis	 poten-
tially	 leading	 to	 lower	 amount	 of	 circulating	 fungal	 antigens	 and	
DNA.20	However,	it	remains	in	discussion	whether	a	different	cut-	off	
for	positivity	should	be	used	 in	patients	with	ongoing	mold	active	
antifungal	prophylaxis	as	supposed	for	BALF-	GM.
Sensitivity	and	specificity	can	only	be	estimated	for	non-	terreus	
Aspergillus	spp.	with	AspID.	Both,	the	QCMD	proficiency	panel	and	
all	 clinical	 samples	 contained	 only	 Aspergillus fumigatus or were 
culture	negative.	None	of	the	samples	tested	contained	Aspergillus 
terreus.	 The	 clinical	 performance	 of	AspID	 regarding	 detection	 of	
Aspergillus terreus	can	thus	not	be	calculated	from	this	study.
Molecular	diagnostic	approaches	for	detection	of	IPA	have	been	
constantly	 improved	 within	 the	 last	 years	 and	 yielded	 promising	
results	 in	clinical	studies,21,22	especially	when	combined	with	anti-
gen	testing.6,13,18	 In	addition,	performance	of	PCR	testing	of	BALF	
samples	 was	 shown	 to	 be	 superior	 to	 PCR	 testing	 of	 blood	 sam-
ples,13	which	is	of	particular	interest	as	bronchoscopy	is	an	invasive	
procedure	that	may	not	be	repeated	as	easy	as	blood	drawing.	This	
may	be	due	to	a	higher	fungal	load	in	the	airways,	the	primary	site	
of	infection.	Also,	systemic	antifungal	therapy	may	significantly	alter	
PCR	performance.	While	antifungal	therapy	seems	to	decrease	PCR	
performance	 in	 blood	 significantly,	 influence	 on	 performance	 of	
BALF	PCR	testing	is	of	less	extent.19,23	One	of	the	major	drawbacks	
for	PCR	assays	used	for	detection	of	Aspergillus	DNA	testing	is	stan-
dardisation.	 Today,	 the	majority	 of	 those	 assays	 are	 still	 based	on	
in-	house	 protocols	 showing	 a	 significant	 interlaboratory	 variation.	
This	may	be	overcome	efficiently	when	employing	 the	AspID	PCR	
which	may	be	a	promising	additional	assay	in	the	armamentarium	of	
diagnostic	tools	for	detection	of	IPA.	In	addition	to	standardisation	
of	 PCR	 assays,	 performance	 of	 bronchoscopy	 and	 BALF	 sampling	
may	also	influence	assay	performance,	for	example	due	to	different	
volumes,	concentrations,	contamination	or	use	of	mucolytic	agents.	
The	 latter	 have	 shown	 to	 significantly	 alter	 the	 performance	 of	
BALF-	GM	 testing.24,25	To	optimise	 reproducibility	of	 study	 results	
both,	standardisation	of	bronchoscopy	and	BALF	sampling	together	
with	improved	standardisation	of	PCR	assays	employing	automated	
nucleic	acid	extraction	platforms	are	warranted.
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Patients with IPA (n = 18)
Patients without 
IPA (n = 18)
Mean	age,	years	(range) 64.5	(48-	84) 66.5	(25-	81)
Male 8 9
Female 10 9
Underlying	risk	factors	for	IPAa
Haematological	malignancy 3 3
ICU	admission 12 13
Solid	tumour 4 4
Autoimmune	disease 2 2
Mold	active	treatment	at	BALF	sampling 5 1
Mean	BALF	GM	levels	(range) 6.9	ODI	(3.2-	25.0) 0.1	ODI	(0.1-	0.3)
Aspergillus	positive	BALF	culture 7b 0
IPA,	invasive	pulmonary	aspergillosis;	ICU,	intensive	care	unit;	BALF,	bronchoalveolar	lavage	fluid;	
GM,	galactomannan;	ODI,	optical	density	index.
aA	patient	may	have	more	than	one	underlying	risk	factor.
b7/7 Aspergillus fumigatus.
TABLE  2 Characteristics	of	the	study	
population	providing	clinical	samples
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